Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.89 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391598 | 1.00 | DPP4 (0.89) | DPP4OPRM1OPRK1 | |
| SCHEMBL386747 | 0.92 | DPP4 (0.92) | DPP4OPRM1OPRK1 | |
| SCHEMBL386746 | 0.92 | DPP4 (0.92) | DPP4OPRM1OPRK1 | |
| SCHEMBL388314 | 0.92 | DPP4 (0.84) | DPP4OPRM1OPRK1 | |
| SCHEMBL8234697 | 0.92 | DPP4 (0.75) | DPP4OPRM1OPRK1 | |
| SCHEMBL389667 | 0.92 | DPP4 (0.84) | DPP4OPRM1OPRK1 | |
| SCHEMBL386997 | 0.89 | DPP4 (1.00) | DPP4OPRM1OPRK1 | |
| SCHEMBL389543 | 0.89 | DPP4 (1.00) | DPP4OPRM1OPRK1 | |
| SCHEMBL390262 | 0.86 | DPP4 (0.77) | DPP4OPRM1OPRK1 | |
| SCHEMBL390263 | 0.86 | DPP4 (0.77) | DPP4OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329900-B2 | Immunosuppressants; autoimmune disease; antiinflammatory agents; multiple sclerosis; rheumatic diseases; antiarthritic agents; aids; preparing, for example, 2-{6-[3-Amino-piperidin-1-yl]-3-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | claimed |
| US-8288539-B2 | Immunosuppressants; autoimmune disease; antiinflammatory agents; multiple sclerosis; rheumatic diseases; antiarthritic agents; aids; for example, 2-{6-[3-Amino-piperidin-1-yl]-3-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | claimed |
| US-8173663-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-08 | — | — | US | claimed |
| US-20090012059-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2009-01-08 | — | — | US | claimed |
| EP-1586571-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | claimed |
| US-20080108807-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-05-08 | — | — | US | claimed |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-05-08 | — | — | US | claimed |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2005-11-24 | — | — | US | claimed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | claimed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | claimed |
| CN-102079743-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-25 | — | — | CN | disclosed |
| CN-102134231-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | disclosed |
| CN-102134229-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | disclosed |
| US-8329900-B2 | Immunosuppressants; autoimmune disease; antiinflammatory agents; multiple sclerosis; rheumatic diseases; antiarthritic agents; aids; preparing, for example, 2-{6-[3-Amino-piperidin-1-yl]-3-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8288539-B2 | Immunosuppressants; autoimmune disease; antiinflammatory agents; multiple sclerosis; rheumatic diseases; antiarthritic agents; aids; for example, 2-{6-[3-Amino-piperidin-1-yl]-3-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20080108807-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-05-08 | — | — | US | disclosed |
| US-20080003283-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY, INC. (JP) | 2008-01-03 | — | — | US | disclosed |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108807-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 2340/4885OPRK1 3648/4885 |
| US-20080003283-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885OPRM1 3481/4885OPRK1 2838/4885 |
| US-20090012059-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 2340/4885OPRK1 3648/4885 |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 2340/4885OPRK1 3648/4885 |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 2340/4885OPRK1 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.